Sitagliptin
486460-32-6
Sitagliptin(INN; previously identified as MK-0431 and sold under the trade name Januvia) is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It was developed and is marketed by Merck & Co. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2.The benefit of this medicine is its lower side-effects (e.g., less hypoglycemia, less weight gain) in the control of blood glucose values. Exenatide (Byetta) also works by its effect on the incretin system.
ACS-PNZ-PYRROLIDYL-(BOC)-NSO2NH2
491878-06-9
2,4-Dichloro-5-nitropyrimidine
49845-33-2 MFCD00127867
3,4-Ethylenedioxythiophene
126213-50-1 MFCD02093622
2-Pyridinol-1-oxide
13161-30-3 MFCD00006195
Irinotecan hydrochloride trihydrate
136572-09-3 MFCD01765731
Cyclopropyl 2-fluorobenzyl ketone
150322-73-9 NULL
3-Bromo-9-phenylcarbazole
1153-85-1 NULL
没有评论:
发表评论